CagriSema (revision 1)
Old revision·23:41, 18 Oct 2024·MergeMorwenna
This is an old revision of this page, as it stood at 23:41, 18 Oct 2024, saved by MergeMorwenna with the summary create article — compound stub. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| CagriSema | |
|---|---|
| Components | Cagrilintide and Semaglutide |
| Form | Fixed-ratio co-formulation, single injection |
| Route | Subcutaneous, weekly |
| Status | Phase 3; not approved |
| Compound infobox · conventions | |
CagriSema is an investigational fixed-ratio combination of the amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, co-formulated for weekly subcutaneous administration in a single injection. It is not approved for use in any indication.[1]
It differs architecturally from the unimolecular dual agonists: rather than one peptide engaging two receptors, CagriSema is two peptides in one syringe. The ratio is therefore set at formulation rather than by chemistry, and the two components retain their own pharmacokinetics — an advantage for design flexibility and a complication for exposure matching.[2]
References
- ^ Frías JP, Deenadayalan S, Erichsen L, et al. "Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial." The Lancet 402(10403):720–730 (2023). PMID 37364590.
- ^ Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." The Lancet 398(10317):2160–2172 (2021). PMID 34798060.
Categories: